Condition: Prostate Cancer · Sponsor: Sir Mortimer B. Davis - Jewish General Hospital
The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after biochemical failure.
This description comes directly from the study's public registry record.
Ashley Feng, M.Sc. · 514-340-8222 · yanqi.feng.ccomtl@ssss.gouv.qc.ca
Always discuss trial participation with your own doctor first.
| CIUSSS du Saguenay-Lac-St-Jean/CSSS de Chicoutimi | Chicoutimi, Quebec, Canada | Recruiting |
| CISSS de la Montérégie-Centre - Hôpital Charles-LeMoyne | Greenfield Park, Quebec, Canada | Recruiting |
| CISSS de Laval - Hôpital de la Cité-de-la-santé de Laval | Laval, Quebec, Canada | Recruiting |
| CIUSSS de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont | Montreal, Quebec, Canada | Recruiting |
| Jewish General Hospital, McGill University | Montreal, Quebec, Canada | Recruiting |
| MUHC - Cedars Cancer Center | Montreal, Quebec, Canada | Recruiting |
| CHU - L'Hôtel-Dieu de Québec | Québec, Quebec, Canada | Recruiting |
| CIUSSS de l'Estrie - Hôpital Fleurimont | Sherbrooke, Quebec, Canada | Not Yet Recruiting |
| CIUSSS de la Mauricie-et-du-centre-du Quebec - Centre hospitalier régional de Trois-Rivières | Trois-Rivières, Quebec, Canada | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02573636